COMMUNIQUÉS West-GlobeNewswire

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance
12/01/2025
ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
12/01/2025
Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, up approximately 366% vs. Q4 2023 and 41% vs. Q3 2024 Preliminary unaudited product revenue for the full- [...]
Lipozem: Introducing Lipozem as the Bizarre Turmeric Hack for Weight Loss Support
12/01/2025
LAKELAND, Fla., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Lipozem emerges in an era where weight management solutions seem endless—from strict diets to high-intensity workouts—yet one groundbreaking discovery is rapidly gaining [...]
iTeos annonce ses priorités stratégiques et ses étapes clés prévues pour 2025
11/01/2025
- Plusieurs extractions de données cliniques issues du programme TIGIT attendues en 2025, portant sur plus de 400 patients issus de deux essais de Phase II et d’un essai de Phase I/II évaluant l’association belrestotug [...]
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/01/2025
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock [...]
Matinas BioPharma Receives NYSE Noncompliance Notice
10/01/2025
BEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that the Company has [...]
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/01/2025
Craig Swandal, experienced medical device manufacturing executive, joins leadership team ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and [...]
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/01/2025
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
10/01/2025
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today [...]
Codexis Announces New Employment Inducement Grants
10/01/2025
REDWOOD CITY, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of [...]
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/01/2025
WOBURN, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of [...]
Yaqrit appoints new CEO Troels Jordansen to implement late clinical development and commercial strategy
10/01/2025
Experienced private and public listed CEO Successful fund raising and business development track record New CEO available during JPM25 in San Francisco LONDON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Yaqrit, a late-stage [...]
Virbac : Declaration of the number of shares and voti
10/01/2025
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 12/2024
10/01/2025
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Ensuring the continuity of IBA's Entrepreneurial Anchoring
10/01/2025
Confirmation of the sale of IBA shares to Management Anchorage Louvain-la-Neuve, Belgium, 10 January 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, confirms that the sale by [...]
Pérennisation de l’ancrage entrepreneurial d’IBA
10/01/2025
Confirmation de la cession d’actions IBA à Management Anchorage Louvain-la-Neuve, Belgique, le 10 janvier 2025 - IBA (Ion Beam Applications SA), le leader mondial de la technologie des accélérateurs de particules, [...]
Adam Ferrari Health Science Scholarship Application Window Closes
10/01/2025
DENVER, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The application period for the 2024 Adam Ferrari Health Science Scholarship , sponsored by The Ferrari Foundation, has officially closed. This $20,000 scholarship program, [...]
Microbot Medical Closes $8.6 Million Registered Direct Offering
10/01/2025
BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the [...]
Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs
10/01/2025
BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, [...]

Pages